-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

Benzinga·08/12/2026 14:00:59
Listen to the news
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.